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Executive Summary 
This report should be read is as an extension to the third publication of the Lancet 
Commission(1), containing new and follow-up metric data around reach of the eight main 
recommendations to reduce the current unacceptable mortality and other harmful 
consequences of excess alcohol consumption, obesity and viral hepatitis. 
The new metrics for alcohol include depressing data on alcohol dependence, damage to 
families and the significant rise in alcohol consumption documented since the removal of the 
tax escalator. Alcoholic liver disease is likely to exceed ischaemic heart disease in terms of 
years of life lost in the near future. This is despite the detailed guidance provided by Public 
Health England (PHE) on optimum alcohol care including brief interventions for which a 
CQUIN has been brought in this year. 
Similarly for obesity, the figures show an increasing disease burden in association with rising 
levels of obesity, more than 60% of adult subjects being overweight or in the obese category.  
Attention is drawn to the small number of bariatric operations being carried out despite 
excellent outcomes in correction of diabetes as well as liver disease.  Some responses by 
industry to the Government’s Soft Drinks Industry Levy, which will formally come into 
effect in April 2018, are being seen, with leading retailers and manufacturers already 
reducing sugar content in key foods and a widening of Government plans to reduce sugar 
content in food stuffs is, again, strongly recommended. The Commission also welcomes the 
recent announcement by the Department of Health and PHE of the next stage of the 
Childhood Obesity Programme, the aim being to remove excess calories from the foods 
children consume the most such as pizzas, savoury snacks and ready meals.  
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The one success this year follows the introduction of the new directly acting antiviral agents 
(DAAs) for the treatment of chronic hepatitis C virus infection (HCV).  For the first time, 
mortality figures for the disease are reduced as well as the number of those with end-stage 
liver disease requiring liver transplantation. More of the presently unrecognised cases of 
chronic HCV in the community will need to be detected if the 2030 elimination goal is to be 
achieved.  Similarly, for chronic hepatitis B infection (HBV) the pool of unrecognised 
infections is a major problem. Universal vaccination of newborns for hepatitis B is now in 
place, along with introduction of a new hexavalent vaccine but vaccination uptake amongst 
the sexual clinics remains less than 80%. 
New metrics for hospital care include an analysis of survival figures for primary 
hepatocellular carcinoma, only a small percentage of cases being diagnosed early enough for 
possible curative therapy. As with other hospital services, provision of care continues to be 
worst in the regions of the country with the greatest socio-economic deprivation. Similarly, 
deficiencies in current training programmes for the specialist registrars (SpRs) are also 
highlighted. Insufficient experience is being obtained by the trainees in units appropriately 
staffed and with the full range of diagnostic and treatment facilities.  
For primary care, the recommendations put forward by the Commission have, encouragingly, 
been taken up the Royal College of General Practitioners (RCGP) and the appointed 
champion for liver disease. New guidance will be published shortly by the British Society of 
Gastroenterology (BSG), on the management of abnormal liver blood tests, with an emphasis 
on potential aetiologies and in establishing severity of fibrosis. Its uptake will need to be 
audited, as will the new disease coding system which is being introduced. 
Finally, the report includes in the centre pages an abridged executive summary from the 
document prepared by the Commission  entitled “Financial case for action on liver disease: 
escalating costs of alcohol misuse, obesity and viral hepatitis”(2). This brings together all the 
evidence available on costs to the NHS and wider society, with alcohol misuse in England 
and Wales costing over £21billion a year, possibly £51billion and with the costs of obesity of 
the order of £27billion a year (although Treasury estimates put it as high as £57billion). This 
is in addition to loss of tax revenue and with the extent of further escalation, the case for 
major control measures becomes ever more telling.  
The overall conclusion has to be that the scale of the medical problems, with an estimated 
63,000 preventable deaths over the next five years along with the costs to wider society, 
public education and voluntary restraints by the food and drinks industry will not be enough. 
Only concerted regulatory and fiscal action by Government will have sufficient effect. The 
number of expert reports during the past year in addition to the Commission’s 
recommendations, leave little doubt over the measures needed. Furthermore, the devolved 
nations - Northern Ireland, Wales and Scotland -as described in this report, are showing what 
can be achieved through strategic planning and selective funding. 
2
 Introduction 
 
This fourth report of the lancet Commission brings yet more factual evidence of the harm 
being done to the nation’s health by excess alcohol consumption, obesity and viral hepatitis 
and the continuing failure to introduce effective measures of control particularly in England 
as opposed to the devolved nations (1, 3, 4). A particularly telling piece of new data came 
with the recent publication of The 2nd Atlas of Variation – Public Health Profiles by Public 
Health England (PHE)(5), showing that the previous steady rise in overall life expectancy has 
stalled and the gap currently between healthy and overall life expectancy is now 16.1 years 
for men, 19.0 years for women (Table 1). Lifestyle causes including smoking have a major 
influence in exacerbating poor health and have been implicated in 30% of dementia cases, 
and alcohol-related liver disease is likely to edge out heart disease as the first cause of 
preventable mortality in the middle age group. With ten million adults regularly drinking 
more than 14 units of alcohol each week - the upper limit of safe drinking for males set by the 
Chief Medical Officer (6), the extent of resulting morbidity and mortality is not surprising 
particularly with  the added influence that excess drinking has on obesity and its spectrum of 
disease complications.  
 
Other important reports on public health have appeared during this past year including The 
2nd Atlas of Variation in NHS Diagnostic Services in England(5), showing deficiencies in 
provision of diagnostic tests for liver disease including Fibroscan®, liver imaging and upper 
GI endoscopy, contributing to the poor provision of health services associated with poverty 
and social inequality in certain regions of the country.  
 
Table 1: Life expectancy data for males and females at birth, England 2013 to 2015 
(Reproduced from data and with permission of Public Health England) 
   
  Males Females 
Life expectancy 79.5 83.1 
Healthy life expectancy 63.4 64.1 
% of life in poor health 20.3 22.9 
 
An important initiative of the Commission this year was in bringing together in a single 
document all the costs of the lifestyle causes including the escalation that can be anticipated. 
The document entitled ‘The Financial Case for Action on Liver Disease – the escalating cost 
of alcohol misuse, obesity and viral hepatitis’(2) was expertly produced by Incisive Health. 
Unless the trend is reversed, the prediction over the next five years is that an additional 
£17billion to the current cost of £20billion will be incurred and the added cost from failure to 
take action on obesity could result in an additional £1.9-£2billion each year. The document, 
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 released on July 24th 2017, attracted considerable media attention(7) and a Parliamentary 
event held in October which included the release of new factfiles on lifestyle costs developed 
for local authorities, saw many Parliamentarians of both Houses attending. Because of the 
importance of the findings, an abridged summary of the document has been included in this 
report. 
 
Another major effort this year has been to bring together all those who are involved in the 
lifestyle causes of disease in the country, so that a single, powerful voice could be put 
forward to Government. Of note is the involvement of the Alcohol Alliance, the Obesity 
Alliance, the Institute of Alcohol Studies and Cancer Research UK together with 
representatives from the London School of Hygiene and Tropical Medicine, the Sheffield 
Alcohol Research Group and the Royal Colleges, along with the Health Departments of the 
devolved nations.  
 
Of considerable relevance to the Commission’s work are the Sustainability and 
Transformation Plans (STPs) of NHS England being developed to achieve a sustained 
improvement in health and social care, around the needs of local populations. As yet little 
information is available on how the forty-four ‘footprints’ that have been set up will 
complement the recommendations put forward by the Lancet Commission.  
 
Recommendation 1: Improving expertise and facilities in primary care to strengthen 
detection of early disease and its treatment, and screening of high-risk patients in the 
community. 
Metrics 1·1-1·4: 
The Royal College of General Practitioners Research & Surveillance Centre (RCGP RSC) 
network has provided data on prevalence and preventative clinical activity within primary 
care. The RCGP RSC is one of Europe’s oldest sentinel networks and has access to 
anonymised data from over two million primary care clinical records(8). The information in 
Table 2 comes from an analysis of adult patient records within its database. 
 
Table 2: RCGP RSC data on Primary Care Activity (patient numbers shown)  
 Numerator Denominator Read coded 
Diagnosis of NAFLD 15,984 1,595,458 1.00% 
BMI recorded in previous 12 months 
BMI recorded in previous 5 years 
421,785 
932,618 
1,595,458 
1,595,458 
26.44% 
58.45% 
Patient’s alcohol units recorded 12 months 
Patient’s alcohol units recorded 5 years 
281,309 
723,279 
1,595,458 
1,595,458 
17.63% 
45.33% 
Alcohol AUDIT recorded in 12 months 
Alcohol AUDIT recorded in previous 5 years 
48,880 
164,743 
1,595,458 
1,595,458 
3.06% 
10.33% 
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 No. injecting drug users with HCV 12 months 
Injecting drug users with HCV 5 years 
50 
118 
1,595,458 
1,595,458 
0.00% 
0.01% 
 
The numbers diagnosed with NAFLD and chronic HCV infection in injecting drug users are 
considerably lower than the known prevalence of these conditions in the population. Potential 
explanations for this include the diagnoses being recorded in ways that are not easily 
searchable in the RCGP RSC database and further investigation is needed to identify barriers 
to the systematic recording and retrieval of liver disease data.  
 
In the future, the RCGP RSC may be able to provide data relating to preventative health 
interventions in signposting patients who misuse alcohol and those who are obese. Data 
relating specifically to the recently published NICE Quality Standards on Liver Disease(9) 
should also become available in the future, with three of the five recommended quality 
statements given below: 
 
1: Advice on physical activity, diet and alcohol to cases of NAFLD. 
2: In NAFLD patients, regular testing for advanced liver fibrosis. 
3: Non-invasive testing of those with risk factors for cirrhosis. 
 
Metric 1·5: 
New coding for liver disease in primary care, necessary for a strategic approach to 
management of established disease, is also the subject of ongoing work. A comprehensive list 
of recommended Read codes that cover investigations for liver diseases including Alcohol 
Related Liver Disease (ARLD), NAFLD and viral hepatitis, have been drafted and will be 
published when the British Liver Trust/RCGP Clinical Priority Programme launches a 
comprehensive web-based liver disease toolkit for primary care in September 2017. Starting 
in April 2018, in primary care there will move away from Read codes to a different 
clinical coding system - the Systematised Nomenclature for Medicine – Clinical Terms 
(SNOMED CT)(10).      
 
In addition to a Read code/SNOMED CT glossary, the BLT/RCGP toolkit will have in-depth 
articles on the major causes of liver disease. It will also contain a database of examples of 
good or innovative practice in preventing or managing liver disease in primary care and in 
collaboration with secondary care facilities. An additional development proposed for the 
database systems is to automatically populate algorithm-based diagnostic systems such as 
Fib-4 (a measure of liver fibrosis) and NFS (non-alcoholic fatty liver disease fibrosis score). 
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Recommendation 2: Establishment of acute liver services in district general hospitals 
linked with 30 regional specialist centres for more complex investigations and 
treatment, and increased provision of medical and nursing training in hepatology 
Metrics 2·1-2·6: 
Follow-up metric data on provision of liver services in hospitals will not be available until the 
next survey of hospitals is carried out in 2018 but important new metrics have been obtained 
on primary hepatocellular carcinoma. Information on how hospital reconfiguration within the 
Sustainability and Transformation Plans to have adequate facilities and staffing for liver care 
(and equitable distribution around the country), is awaited. Linking with the recommended 
thirty regional centres for more specialist work also remains to be determined. The 
operational delivery networks (ODNs) that have been set up to deliver the very costly of anti-
Box 1:  Liver disease in primary care – an example of best practice.  
Dr Mead Mathews, GP Partner in Southampton with special interest in liver disease. 
 
The St Marys’ surgery in Southampton took part in the LOCATE study and as a result concluded that 
the management of liver disease needed updating. Although Locate had defined an at risk 
population there was difficulty getting them to engage with only a 7% response rate to invitations 
to a nurse led liver clinic. This work was felt to be important as St Mary’s is a large inner city 
practice, with much deprivation, immigration and potentially undiagnosed liver disease.  
Using the Lancet proposed primary care pathway as a starting point, a clinical pathway was 
developed with the local hepatology department and a short term agreement made for direct 
fibroscan access. An at-risk population was defined and a flag added to the primary care records. 
On opening the notes a protocol is triggered that says “this patient is at risk of liver disease please 
consider a liver conversation”. The aim behind this was to fully integrate the risk alert and 
consultation in to the primary care consultation making a “liver status check” as commonplace as 
discussing blood pressure.  
To raise GP awareness and engage enthusiasm the surgery liaised with the British Liver Trust, who 
lent promotional material, and in September 2016 the practice launched its first liver campaign – 
the surgery was decorated, the waiting room promotional material directed patients to ask for a 
liver check and a new template was installed so that doctors could code and track patients along 
the pathway. The development of the template and recall process was the most difficult part of the 
project due to the lack of suitable Read codes.  
The practice trained two nurses in liver disease, with anecdotal evidence of good initial changes in 
behaviour modification even pre-fibroscan. Of the 2700 patient at risk population 430 have been 
placed on the pathway to date.  Early on in the data collection, it was found that patients who had 
failed to attend hepatology appointments in the past were re-engaging. 
The project has led to more appropriate referrals and a reduction in unnecessary repeated 
blood/ultrasound ordering and it has now moved on with the development of a joint run practice 
based fibroscan clinic. A presentation of the pilot trial led to the local CCG asking to use the 
pathway to update local guidance. 
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 HCV drugs (see later in this report) represent a new approach to delivery of care for liver 
disease patients. 
 
Hepatology Training and Capacity 
The biannual surveys performed by the Trainees section of the British Society of 
Gastroenterology (BSG) have consistently reported low levels of confidence in managing 
certain aspects and conditions within Hepatology, even among senior trainees. A common 
theme in all the recent surveys is a lack of confidence in managing outpatient Hepatology, 
particularly viral hepatitis, autoimmune liver disease and liver transplant patients (timing of 
referral, indications for transplantation and post-transplant management). This is a major 
concern when up to 30% of trainees are reporting a desire to sub-specialise in Hepatology, 
with an additional 15% considering such a career move. The main barriers reported by them 
were a lack of local training opportunities and not wishing to change regions to obtain liver 
training. 
 
At present, all trainees in Gastroenterology are expected to receive 6 months training in a 
Level 2 or Level 3 unit.  Level 2 is one that provides: ≥2 Whole Time Equivalent (WTE) 
consultant Hepatologists, out of hours endoscopy including management of varices, 
transjugular intrahepatic porto-systemic shunts (TIPSS), an hepatocellular 
carcinoma/hepatobiliary (HCC/HPB) multi-disciplinary meeting, loco-regional ablation 
treatments for HCC, antiviral treatment for hepatitis C as part of an Operational Delivery 
Network (ODN), liver histopathology, dedicated liver clinics, and a specialist nurse team 
including alcohol liaison. A Level 3 unit has in addition a liver transplant programme. 
 
In fact, as shown in Figure 2, most of the trainees are spending the majority of their time in 
Level 1 units and with < 50% having experience of Level 2 hepatology training and just 40% 
gaining experience of Level 3. Furthermore, information from the Deanery Programme 
Directors revealed a marked difference between the number of centres in the UK currently 
being used for Level 2 training (n=47) and the number (n=19) having the necessary range of 
staffing and services, as identified in the UK survey of Liver Services carried out in 2015-16. 
There are also missed opportunities for training in the distribution of training units, as shown 
in Figure 2. 
 
To correct the potentially dangerous present situation and ensure that trainees do gain 
appropriate experience, only designated Level 2 units should be used. It is also recommended 
that a period of six months be spent in an enhanced Level 1 unit providing experience in out 
of hours endoscopy, with links to a major centre for HCC/HPB management, dedicated liver 
clinics, a specialist nurse team, and ≥1 WTE Consultant Hepatologist. 
 
Training capacity In England has also been examined. This assumes that each centre can 
accommodate two trainees per six months over the five years of the training programme i.e. a 
deanery with Level 2 or 3 centre can accommodate twenty trainees. Currently, there are 
deaneries without sufficient capacity for “Enhanced” Level 1 training, namely London NE 
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 and the North East and there are potentially seven deaneries without sufficient capacity for 
Level 2 and Level 3 training. 
 
Figure 1 Senior Trainees (ST6/7/8 & SpR) were asked to identify duration of Level 1, 2 
& 3 Hepatology training 
 
 
 
Figure 2: Current distribution of agreed training centres in England in relation to 
hospital admissions for liver disease of all ages (standardised rates per 100,000 
population, 2014-15) showing poor provision in some areas of high prevalence. 
Map prepared under licence by Public Health England. © Crown copyright and database right 2017. 
Indicator source: PHE, Liver Disease Profiles, Indicator 90892; Numerator source: Hospital Episode 
Statistics; Denominator source: ONS 2011 Census based mi-year population estimates. 
 
Training centres 
Enhanced Level (27) 
Level 2 (15) 
Level 3 (6) 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
New Metric for Primary Hepatocellular Carcinoma: 
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 Figure 3 shows a considerable variation in mortality rates for primary hepatocellular 
carcinoma between the regions, as mapped by the STPs, a reflection again of the greater 
burden of disease and lack of specialist services in the more deprived areas. For 2011-15, 
values ranged from 1.2 to 3.0 per 100,000 population - a 2.6-fold difference in the mortality 
rate between STPs. The median value increased significantly from 1.4 per in2005-09 to 1.8 
per 100,000 population in 2011-15.  
 
Figure 3:  Box plot showing variation in mortality rate under 75 years due to 
Hepatocellular Carcinoma by Sustainability Transformation Plan (2011-2015); 
standardised mortality per 100,000 Population 
 
The percentage of persons aged 15 years and over with hepatocellular carcinoma that are 
receiving treatment with curative intent (liver transplantation or major liver resection or 
ablation) is depressingly low at around 16% (Table 3). There is also considerable variation 
(1:5 fold) between the geographical regions from 11.4 to 17.3%. 
 
Table 3: Percentage of cases aged 15 years and over with hepatocellular carcinoma 
receiving treatment with curative intent (liver transplantation, major liver resection or 
ablation) within 6 months of diagnosis, by region (2010-2014) (Data from PHE) 
 
 Diagnosed Number treated and %  
East Midlands 710 112              15.8% 
East of England 1,038 167              16.1% 
London 1,323 204              15.4% 
North East 676 77               11.4% 
North West 1,667 270              16.2% 
South East 1,342 188               14.0% 
South West 1,059 173               16.3% 
West Midlands 1,043 180               17.3% 
Yorkshire and The Humber 1,119 193               17.2% 
England 9,977 1,564             15.7% 
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Variation in mortality rate in people aged under 75 years due to hepatocellular carcinoma per population by Sustainability Transformation Plan (STP) (2011-2015)
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 Figure: 4     Executive Summary of the Financial Case for Action on Liver Disease(2) 
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 Recommendation 3: A national review of liver transplantation to ensure better access 
for patients and to increase capacity 
Metrics 3·1 – 3·5: 
1003 transplants were carried out in 2016 (children included) representing a significant 
increase over previous years. The breakdown into donation from donors after brain or cardiac 
death and after living donation, is also illustrated in Figure 5. The number of transplants 
carried out is still less than the number of new registrants added to the Waiting List – 1169, 
with 600 previously registered. 13% (72) of those on the waiting list died or were removed 
(168) as they had become too sick. The 30-day survival rates for elective transplantation, the 
traditional metric used in Qusum analyses to monitor performance, are excellent at 95-100%. 
However, 5-year survival rates are not consistent across the transplant centres. 
 
Of the new initiatives being developed to expand the donor pool, normo-thermic machine 
perfusion is particularly promising. This should decrease the proportion of potential grafts 
considered unsuitable for implantation (15% of donated organs in 2016/17) and is likely to 
have most impact on donation after cardiac death. A pilot study is under consideration to 
extend to those in urgent need of transplantation, the use of organs from Hepatitis C positive 
donors, this being linked to guaranteed access after surgery to the new, effective directly 
acting antiviral agents. 
 
Encouraging also is the increase in organ donation rate in Wales during the first twelve 
months after introduction of presumed consent, with an increase in all transplants from 120 in 
2014 to 160 at year end 2016, accompanied by a rise in the family consent rate from 49 to 
59%. Living donors increased by 20% compared with 2% fall across UK. A quarter of the 
donations in Wales came from "presumed consent" dispelling doubts that this would 
discourage good will towards donation.  
 
The new national offering sequence for donation is scheduled to start operating from 
December 2017 for donors after brain death, with extension to donors after circulatory death 
thereafter. With the first offer of an organ no longer being directed to the centres but to the 
highest ranked suitable patient in the UK, transplant benefit should be maximised as well as 
equity of access for patients. It should also provide information on the current variation 
between centres in the acceptance rate of donated organs.  
 
Essential within the strategic review NHS England is due to carry out in 2018, will be an 
examination of increasing capacity within current centres, as opposed to the setting up of new 
centres to provide more equitable and better access for the patients.  
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 Figure 5:  Annual number of liver transplants in the UK, 2007/8-2017/17 (data from 
NHS Blood and Transplant) 
 
Recommendation 4:     Specialist paediatric services and continuity of care in transition 
arrangements for children with liver disease reaching adult life. 
Metrics 4·1-4·3 
Data on the number of children born at term with persistent conjugated jaundice lasting 
longer than 14 days in term babies and 21 days in pre-term, referred to the three national 
paediatric liver units before 8 weeks old, is shown in Table 4 (comprising Metric 1·6 in the 
2015 Lancet report).   
 
Table 4: Conjugated jaundice (aged <6 months) and diagnosis of extra hepatic biliary 
atresia in referrals to the three National Paediatric Liver Units 2012-2017. 
 
Centre Referrals 
(number) 
EHBA 
(number) 
Median age and 
range (days) 
EHBA > 56d 
BCH 661 69 49 (10-104) 15 (0.7%) 
KCH 902 126 50 (0-242) 31 (1.4%) 
Leeds 554 63 34 (4-126) 10 (0.5%) 
Total 2117 258 45 (0-242) 56 (2.6%)  
 
BCH:  Birmingham Children’s Hospital,   KCH: King’s College Hospital  
 
Over the five year period 258 (12%) children were diagnosed with extra hepatic biliary 
atresia (EHBA). The majority were referred before 56 days of age, at a median age of 45 days 
but the range was wide (0-242 days) and 56 children were referred after 56 days. This is too 
13
 late for a benefit to be obtained from early surgery(11) and demonstrates the need for 
continued education and awareness of the importance of early diagnosis of neonatal liver 
disease.  
An electronic questionnaire on continuity of care in transition arrangements for children with 
liver disease reaching adult life, prepared in collaboration with the British Society for 
Gastroenterology, will be sent to adult gastroenterology and hepatology units who have >3 
WTE hepatologists or who meet Level 2 training criteria. A draft document specifying 
training requirements for Physicians caring for young adults with liver disease has also been 
submitted to the Specialist Advisory Committee in Gastroenterology and the management of 
childhood liver disease including the transition period featured in a recent publication in the 
Journal of Hepatology(12) but no metric data is available at present on what arrangements are 
in place.  
 
Recommendation 5:  Measures to reduce overall alcohol consumption in the country  
 
Metric 5·1:  Alcohol policy 
Since 2013, when the 2% above inflation alcohol duty escalator was abolished, death rates 
have increased again. A report by PHE on an evidence based alcohol policy was published as 
a peer reviewed paper in the Lancet(13) and is currently with ministers for review, having 
been submitted to them in late 2016. It confirms findings of previous reports, most recently 
by the OECD(14), that fiscal policy is by far the most effective and cost-effective policy 
option, with effective regulation of alcohol marketing an important step in reducing the 
exposure of children to marketing pressures.    
The situation in Scotland is more promising with a final Supreme Court decision on 
Minimum Unit Pricing (MUP) expected in October 2017 and with the Scottish government 
anticipating being able to action the law early in 2018. Wales is following  a similar path and 
the comprehensive new alcohol strategy of the Irish government includes MUP and strong 
regulation of marketing with a variant of the French Loi Evin(15). The scenario is therefore 
set for the most important natural experiment on alcohol policy in decades, with England in 
the role of placebo control.  
 
Metric 5·2: UK Alcohol Consumption and Dependency 
Alcohol consumption, which peaked at around 5,642,000 hl (hectolitres) in 2008/9, dropped 
when the duty escalator was introduced to around 4,843,000 hl in 2013/4. Since it stopped, 
consumption increased again to 5,126,000 hl in 2016/7. Total alcohol clearances have been 
estimated using a figure of 5% for cider and 13% for wine (data from the HMRC Alcohol 
Bulletin, May 2017). These changes illustrate how responsive population alcohol 
consumption is to small changes in taxation. 
Key numbers in a recent study on prevalence of alcohol dependence in England by local 
area(16) defining the extent of the problem, were as follows:- 
 595,131 adults with alcohol dependence in England, which represents 1.39% of the 
18+ population 
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  313,753, the majority, display mild dependence, followed by 173,399 with  moderate 
severity and 107,979 with severe dependence  
 120,419 alcohol dependent adults are estimated to have children living with them in 
the household, totalling 207,617 children  
 57% of alcohol dependent adults have a desire to cut down their drinking and 41% 
intend to do so “in the near future” 
 
These figures are to be compared with the number of people accessing specialist alcohol 
treatment, as recorded in England by the National Drug Treatment Monitoring System. Since 
2008 this has increased slightly from 107,218 in 2008/09  to 113,222 in 2015/16 (Table 
5)(17). Scotland does not have an equivalent monitoring system, but treatment access surveys 
on waiting times in Scotland provide estimates of the number of people accessing 
treatment(18) and show proportionately a greater number:  from 16,952 in 2008/09 to 28,500 
in 2015/16. This increase in alcohol treatment numbers coincided with an additional annual 
investment in treatment services of £28million, taking the total alcohol treatment budget from 
approximately £61million to £89million. There was no equivalent increase in the alcohol 
treatment budget in England over the same period.  
 
Furthermore, the ratio of treatment access to alcohol dependence admissions which serves as 
a proxy indicator of the prevalence in the general population, reduced slightly from 1.56 to 
1.40 between 2008/09 to 2015/16, whereas in Scotland the ratio increased considerably from 
1.75 to 2.69, amounting to a two-fold difference, providing additional evidence of the need to 
upgrade measures to reduce the present levels of consumption and dependence in England.  
 
Metric 5·3: Hospital admissions 
Of the two official measures of alcohol related hospital admissions, the broad measure 
includes both primary and secondary diagnoses and is a more accurate reflection of the total 
burden of alcohol related harm. The newer, narrow measure introduced in 2014 to 
compensate for changes in coding includes only primary diagnoses of an alcohol related 
cause and is substantially lower than the broad measure(19). During 2015/6 there were 1·1 
million broad measure admissions representing 7% of total hospital admissions, an increase 
of 4% compared with the previous year and the narrow measure increased by 3% to 339,000 
admissions(20). The peak age group for admission was 45-54yrs, and 39% of patients were 
aged 45-64yrs. 61% were male. Blackpool had the highest number (3,540/100,000 
population) and Kingston upon Thames the lowest (1,400/100,000). The narrow measure 
increased from 69,270 in 2014/5 to 75,160 admissions in 2015/6, an increase of 8.5% (Figure 
5). In-hospital liver mortality continues to fall, possibly as a result of improved inpatient care, 
but there are worrying signs that this has not translated into an improvement in long term 
survival(20). 
 
 
 
Figure 6: Alcohol related hospital admissions in England(13) 
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Metric 5·4: Alcohol related mortality and years of life lost 
As shown in the heatmap (Figure 8), there is close correlation between liver disease mortality 
and the socio-economic deprivation index. Mortality is mainly seen in the young and middle 
aged group. In 1979 ischaemic heart disease (IHD) resulted in 12.6 times as many years lost 
as liver disease, lung cancer 3.2 times and breast cancer 2.4 times. In 1999, liver disease 
outstripped lung cancer and breast cancer and is finally set to outstrip ischaemic heart disease 
as the leading cause of working years of life lost. 
Figure 7: Potential years of working life lost (prior to age 65) estimated using ONS 
mortality 1979-2015(21, 22) categorised into 5 year age bands. (analysis by Nick 
Sheron).  
 
Figure 8: Heat map showing mortality rates per 100,000 of population attributable to 
alcoholic liver disease by age and IMD (Index of Multiple Deprivation) quintile. Stark 
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 socioeconomic inequalities are shown, with the highest density of deaths indicated by 
dark colours, in the middle-aged deprived population. Data analysis Petra Meier and 
Colin Angus. 
 
 
Metric 5·5: Hospital and Community Alcohol Services 
A total of 144,908 individuals exhibiting problematic or dependent drinking presented to 
specialist alcohol treatment in England in 2015/16 (Public Health England 2016). Of these, 
85,035 were treated for alcohol only and 59,873 for alcohol problems together with other 
substances. The overall number of individuals in treatment for alcohol alone fell by 4% 
compared to 2014-15, with the numbers for alcohol and other substances decreasing by 5% 
since then(23). 
 
Ensuring access to specialist alcohol treatment in the community is a key element of the 
WHO Global Alcohol Strategy which advocates “Individuals and families affected by the 
harmful use of alcohol should have access to affordable and effective prevention and care 
services.”(24). One UK study of psychosocial treatment for alcohol dependence showed 
savings to the public sector of £5 for every £1 spent(25). A recent economic analysis by PHE 
also concluded that alcohol screening and brief interventions, together with Alcohol Care 
Teams and Alcohol Assessment Outreach teams proactively engaging with social care 
services, will return exponential savings over the cost of delivery(13). 
 
In 2017/18, a national prevention Commissioning for Quality and Innovation scheme 
(CQUIN) including alcohol was implemented in mental health and community trusts, with 
secondary care to follow in 2018/19. Hospital trusts who deliver identification and brief 
advice (IBA) to 80% of patients will receive financial reimbursement. To support local 
planning and commissioning in relation to the CQUIN, PHE published local guidance(26) 
which includes the following recommendations: 
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1. establish and / or optimise alcohol care teams in district hospitals 
2. provide alcohol IBA in primary and secondary care settings 
3. establish alcohol assertive outreach teams 
4. establish clear care pathways for sustained engagement with high volume users 
5. Prompt access to treatment services for parents identified as harmful/dependent 
drinkers with agreed pathways to reduce risks to children. 
 
Although published plans for STPs mention some action on alcohol, it is not possible to 
know if this relates to the optimisation of existing services or the implementation of a new 
service, or how closely the proposed arrangements mirror PHE’s best practice guidance 
alone(26). 
Whether the situation will be improved by the recently announced Government Drug Strategy 
2017(27), which highlights the importance of preventing drug and alcohol misuse, with an 
emphasis on investing in a range of evidence based programmes, remains to be seen.  
 
Table 5: Access to specialist alcohol treatment, alcohol dependence hospital admissions 
and treatment access ratios in England and Scotland 2012/13 to 2015/16. 
 England Scotland 
Year Treatment 
access 
Hospital 
admissions* 
Access 
ratio 
Treatment 
access 
Hospital 
admissions* 
Access 
ratio 
2012/13 115,171 77,820 1.48 32,000 10,320 3.10 
2013/14 120,522 79,920 1.51 30,601 10,885 2.81 
2014/15 117,235 80,220 1.46 29,515 10,749 2.75 
2015/16 113,222 81,080 1.40 28,500 10,581 2.69 
*ICD-10 F10.2, F10.3, F10.4 
 
Recommendation 6:  Promotion of healthy lifestyles to reduce obesity and the burden of 
NAFLD 
 
Metrics 6·1: 
New data has been added for each of the metrics in this section. The trend in prevalence of 
adult obesity (body mass index ≥ 30kg/m2) in England, Wales, Scotland and Northern Ireland 
is shown in Figure 8 below, using data from the Health Survey for England and equivalent 
surveys in Wales, Scotland and Northern Ireland. All countries show a rising trend in 
prevalence. The Welsh Health Survey uses self-reported data, that tend to understate the 
prevalence of obesity(28), while the other surveys use measured height and weight data. This 
may account for the lower reported prevalence in Wales.  
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 There is a lack of comparable data on childhood obesity from across the UK, with Wales 
publishing data on a different age group from England and Scotland, and Northern Ireland 
using a different definition (International Obesity Task Force thresholds rather than the UK90 
cut-offs)(29). Data that are available appear to show a tendency towards a levelling off in the 
prevalence of childhood obesity, although the average figures are likely to conceal widening 
inequalities in socio-economic distribution, by ethnicity, and in severity(30, 31). 
 
Figure 9: Adult (aged 16+) obesity (body mass index ≥ 30kg/m2) prevalence in England, 
Wales, Scotland and Northern Ireland 1993-2015 
 
 
Metric 6·2 Progress against Health Select Committee recommendations 
The Government’s child obesity plan from 2016 remains unchanged as the primary statement 
of policy in this area(32). Developments in terms of the industry’s responses to the 
Government’s Soft Drinks Industry Levy (SDIL) are expected to take effect from April 
2018(33). Levy rates of 18p/l for drinks with an added sugar content above 5g/100ml, and 
24p/l for drinks with an added sugar content above 8g/100ml, were set out in the Finance Act 
2017(34) and a number of soft drinks manufacturers have already started to reformulate their 
products to the extent that the Treasury now anticipates reduced revenue from the levy(35). 
Along with a growing evidence base on the effectiveness of taxing sugar sweetened 
drinks(36-38) which is also underway, it will be important to evaluate how the UK approach 
plays out over the medium to long term, taking into account the complexity of public, 
political and industry responses(39) and whether the current exclusion of foodstuffs from the 
levy will be lifted. 
In addition, during 2017 Public Health England have published guidelines for industry on 
reducing the amount of sugar in children’s diets(40), guidance for Local Authorities on 
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 commissioning adult weight management services (41) and on encouraging healthier out of 
home food provision (42), and guidance on healthy spatial planning(43). 
 
 
Box 2: The Bolton Experience 
Dr Stephen Liversedge from Bolton reports on working with patients found to have a HbA1C 
in the pre-diabetic range. They were entered into a programme with his Health Improvement 
Practitioners based on diet and exercise. The patients had never taken dieting for their obesity 
seriously before but when worried about diabetes, they lost an average of 9.5 kg in 1 year. 
Funding for Health Improvement Prevention was by CCGs after Local Authority cut backs. 
 
6·3 Prevalence of NAFLD/non-alcoholic steatohepatitis in secondary care 
The number of finished consultant episodes annually as a marker of hospital activity, which 
were given in last year’s report, have shown a further rise in the latest figures from NHS 
Digital: from 4,085 and 3.040 in 2015-15 for England and Wales, to 5,361 and 3,534 
respectively in 2015-16(44). 
 
The growing disease burden in hospitals from NAFLD is also reflected by the numbers of 
patients being listed for transplantation. NAFLD is now the second commonest indication for 
liver transplantation in the UK, behind only alcohol-related liver disease (Figure 10). The 
figures are a summation of those coded as NASH (14.4%) and as cryptogenic cirrhosis 
(3.8%). 
 
Figure 10: Aetiology of liver 
disease patients on liver 
transplant waiting list as of 
January 2017  
 
ARLD - Alcohol related liver disease;  
NASH - Non-alcoholic steatohepatitis;  
PSC - Primary sclerosing cholangitis;  
HCV - Hepatitis C infection;  
PBC - Primary biliary cirrhosis; AIH - 
Autoimmune hepatitis;   
HBV - Hepatitis B infection 
 
 
Metric 6·4: Number of primary bariatric surgery operations  
Around 2 million people in the UK, it is estimated, fulfil NICE eligibility criteria for bariatric 
surgery (BMI ≥ 35 kg/m2 with an obesity-associated co-morbid condition or BMI≥40 kg/m2). 
Liver disease (NAFLD) is either the indication for bariatric surgery or a co-morbid diagnosis 
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and in the most recent financial year, 9% of all patients undergoing bariatric surgery had a 
diagnosis of liver disease. 
Despite the effectiveness of the procedure in terms of diabetes and disease reversal, quite 
apart from desired loss of weight, less than 6,000 operations were undertaken in 2016 which 
is fewer than <0.01% of the eligible population. The more recent data from the Health and 
Social Services Information Centre indicate an almost 10% fall in the number of bariatric 
surgery procedures (Figure 11) and was highlighted in last year’s report, there can be no 
justification for this marked under provision of bariatric surgery in the UK. 
Figure 11: Number of primary bariatric operations performed annually in the UK 
Recommendation 7:    Elimination of chronic HCV infection from the country by 2030 
and a major reduction in the burden of disease for hepatitis B 
Metric 7·1: Number of HCV-infected patients treated with new HCV direct-acting 
antivirals and number achieving cure or SVR12 (linked with WHO indicator 8). 
The efficiency, ease of use and overall safety of the new directly acting antiviral agents 
against HCV infection have enabled real progress to be made in the UK in the goal of 
elimination of this infection and reduction of the associated burden of liver disease.  NHS 
England data shows the 22 HCV Operational Delivery Networks have been able to treat 
10,054 cases between April 2016 to March 2017, and plans are now in place to treat 12,500 
in 2017/18.  An interim analysis of Sustained viral response (SVR) data from the national 
programme in England completed in November 2016 showed that of patients who were alive 
21
 three months after cessation of therapy and for whom data was available, 92.4% of patients 
had achieved SVR(45). 
 
Similarly for Scotland, 1,685 patients were treated between April 2016 and March 2017 (35% 
with Fibrosis stage 3-4) (46) and in Wales, the 781 treated patients had a predicted/estimated 
SVR of 95%. In Northern Ireland, of the 105 patients treated between March 2015 and July 
2016, an SVR was achieved 95% of cases.  
 
Metric 7·2: Number of patients diagnosed with HCV and HBV  
HCV: on the background of a steady increase in the number of laboratory confirmed reports 
of HCV in England since the 1990s, there were in 2015 11,605 laboratory reports of 
individuals testing positive for antibodies to HCV. Consistent with this, testing from twenty-
three sentinel laboratories showed a rise in tests undertaken of 18.6% between 2011 and 2015 
(Figure 12), although the proportion of positive results declined from 2.6% in 2011 to 1.5% 
in 2015. The inference from this is that the number of new diagnoses made will have to 
increase considerably if the planned rise in treatment numbers is to be sustained(47). 
 
The situation in the drug addiction clinics where most cases of HCV infection are 
encountered is far from satisfactory. Only around half of patients who inject drugs (PWID) 
sampled in UK surveys are aware of an HCV antibody positive status and this figure has 
remained relatively stable over the last 6 years. Surveys do not show any reduction in the 
numbers of new HCV infections over recent years. The estimated prevalence of HCV 
infection in recent initiates to drug use (started within the last three years) was 27% in 2016 
compared to 24% in 2008 and moreover the proportion of PWID reporting adequate 
needles/syringe provision was found to be sub-optimal, with only about one half of those 
surveyed reporting adequate provision for their needs. These findings suggest that the WHO 
Global Health Sector Strategy(48) call to reduce new cases of chronic HCV by 30% by 2020 
and 80% by 2030, represents a significant challenge for the UK health services. 
Figures for the devolved nations show a significant reduction in number of new diagnoses 
following the introduction of the DAAs. In Scotland, the number of new cases of Hepatitis C 
antibody positivity fell to 1594 between January and December 2016, compared to a figure of 
1815 for 2015. In Wales, provisional data from laboratory reports showed a reduction in new 
HCV antibody positive cases  - 531 were diagnosed in 2016 compared to 612 in 2015, and in 
Northern Ireland, the number of new laboratory confirmed antibody positive reports for 2016 
was  down 13 % on the figure for 2015. Previously, for all three countries numbers had been 
rising steadily. 
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 Figure 12: Number of laboratory reports of hepatitis C from England: 1996 to 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HBV infection  
No new data is available on the number of HBV diagnoses for England since the 2015 data 
given in the last Lancet report. Figures for Scotland are also awaited, as are those for Wales. 
In Northern Ireland, a total of 101 Hepatitis B infections were reported in 2016, of which 18 
were new antenatal cases, compared to a total of 91 Hepatitis B infections reported in 2015 of 
which 11 were new antenatal cases. In people who inject drugs (PWID), the Unlinked 
Anonymised Monitoring Survey(49) shows the prevalence of antibodies to the hepatitis B 
core antigen (anti-HBc, a marker of past or current infection) across England, Wales and 
Northern Ireland, has significantly declined since 2006 from 26% down to 13% in 2015 
(Figure 13). Figure 13 also shows that uptake of the hepatitis B vaccine is stuck at around 
75%, with at least 20% not being protected. 
 
Figure 13: Prevalence of anti-HBc and uptake of the vaccine against hepatitis B among 
participants in the Unlinked Anonymous Monitoring Survey of PWID: England, Wales 
and Northern Ireland 2005-2015 
 
 
 
 
 
 
 
 
 
 
 
 
23
 Metric 7·3: mortality from HCV and HBV  
A recent report(47) compiling data from different sources or England, Scotland, Wales and 
Northern Ireland suggests that the number of new cases of HCV-related end-stage liver 
disease (ESLD) or hepatocellular carcinoma (HCC) remained fairly stable at around 1875 
new cases/year (range 1809-1933) from 2011-2015. Similarly, the number of liver transplants 
undertaken for HCV which had remained relatively stable between 2008 and 2014, decreased 
by 32%  - from 122 transplants in 2014 to 83 in 2015. This was the first year in which the 
new DAAs were used in advanced liver disease. Deaths from ESLD or HCC rise steadily 
from 215 in 2005 to 456 in 2014 but have dropped in both 2015 and 2016. The preliminary 
data for 2015 initially suggested an 8% fall in deaths but this figure was subsequently revised 
to 3%. The preliminary figures for 2016 suggest a further 7% fall in England, Scotland and 
Wales but again these figures remain provisional. This suggests that new drugs may already 
be having an impact on mortality from HCV-related ESLD and primary HCC.  With the 
World Health Organisation GHSS global health strategy for a reduction in HCV related 
mortality of 10% by  2020(48) and a reduction of at least 65% by 2020, seems achievable. 
 
Figure 14: Deaths from HCV-related ESLD* or HCC in the UK: 2005 to 2016 
 
 
 
 
 
 
Mortality figures from chronic HBV infection though greatly reduced following introduction 
of nucleoside drugs which inhibit viral replication, are still being affected by instances of 
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 viral reactivation and the risk of primary HCC long term is not completely eliminated.  With 
the new curative drugs for HBV under clinical trial being developed, it is strongly 
recommended that funding and administrative arrangements be put in place, as has been so 
successful for the new anti-HCV agents. Similarly, the substantial current undiagnosed pools 
of chronic HBV infection in the community need to be addressed through screening 
procedures at general practice level. 
 
Metric 7·4: numbers of infants starting and numbers completing a course of HBV 
vaccination 
The figures for 2016-2017 in England are encouraging, with data from the COVER 
programme(50) showing that of a total of 2245 infants born to HBsAg positive mothers, 85% 
completed a course of three vaccinations by twelve months of age and 69% had completed 
the full course with a fourth dose by the age of two years, compared to 2010 when there was 
88% at one year and 72% at two years reported in 2015-16(50). Similar data from Wales 
shows 94% completion of a course of three vaccinations by 12 months of age and 90% 
completing the full course with a fourth dose by the age of two years(51). 
 
Metric 7·5: Universal vaccination for HBV (Yes or No?) 
This, at long last, it can be reported is now in place and later this year a new hexavalent 
vaccine will be introduced for primary baby immunisations across the UK, providing 
protection against diphtheria, tetanus, pertussis, polio and Hib as well as the hepatitis B virus. 
All babies born on or after 1st August 2017 will become eligible for the vaccine Infanrix 
hexa® (DTaP/IPV/Hib/HepB) starting from late September/early October 2017, at the ages 
of eight, twelve and sixteen weeks as part of the routine childhood immunisation schedule. 
 
Recommendation 8:   Increasing awareness of liver disease in the general population 
and within the NHS; work of liver patient support groups. 
Metric 8·1-8·4:  Public Health Campaigns and Patient Representation  
The year covered by this report has seen even greater media involvement and continual 
campaigns by the Children’s Liver Disease Foundation (CLDF) and the British Liver Trust 
(BLT). The CLDF Yellow Alert Campaign aims to highlight the signs and symptoms of 
neonatal liver disease in order to prompt early diagnosis, has over the last five years 
distributed 14,000 yellow alert protocol packs to health care professionals with a further 
35,000 being downloaded from the website. The British Liver Trust’s campaign, known as 
Love Your Liver (www.loveyourliver.org.uk), comprises an easy to use screener for the three 
main preventable causes of liver disease. Over the last three years more than 80% of 98,237 
completions of the online screener showed risks that could cause liver disease. 2126 of 2669 
people who attended a screening and scanning event over the past five years were found to be 
at risk of liver disease and 496 were referred for further tests. The annual Love Your Liver 
week also includes a screening and scanning roadshow. Of note too is the Welsh Liver Plan’s 
implementation committee which has representation from the CLDF and BLT, and funding to 
run twenty screening and scanning events over the next two years. PHE have also been active 
with public awareness campaigns on obesity and alcohol although not one specifically for 
liver disease. 
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 After a small pilot study involving a limited number of hospitals, the Royal College of 
Physicians (RCP) has officially launched its new exemplar liver accreditation programme, 
Improving Quality in Liver Services (IQILS), led by Dr James Ferguson. Open to all liver 
services across the UK, it gives them access to a new online tool and up to date guidance on 
improving standards. In addition, NICE has this year published a quality standard for liver 
disease(9) which sets out what is expected of service providers in caring for patients with 
liver diseases.  
 
Progress Reports from the Devolved Nations 
New data relating to alcohol, obesity and viral hepatitis has been largely given in the relevant 
sections of this report and the following is concerned more with strategy and new planning. 
Scotland 
The Scottish Government will be publishing a refresh of its alcohol strategy later this year in 
tandem with this Scottish Health Action on Alcohol Problems (SHAAP) and with the support 
of the Scottish Royal Colleges which will recommend methods to improve early 
identification of alcohol related liver damage to focus alcohol treatment services more 
effectively on those at greatest risk of alcohol related liver disease. The Scottish Government 
has also commissioned a programme of research to establish the impact of implementing 
minimum unit pricing subject to the outcome of ongoing legal challenge. With about 80% of 
the estimated prevalent cases of HCV diagnosed, bringing the remainder to cure is involving 
innovative pathways of care, including delivery of treatment and care by community 
pharmacists. The University of Dundee is leading a regional trial of “treatment as prevention” 
for HCV to develop a blue print to achieve elimination of HCV, fulfilling Scotland’s 
commitment to the WHO elimination targets. A pilot study of automated reflex aetiological 
screening for liver disease, where screening tests are performed on the index blood sample 
immediately an abnormality is detected, has shown the process to be highly effective in 
diagnosis and cost-effective. It is currently being implemented in some of the health boards in 
Scotland. 
Northern Ireland 
The NICE guidelines on NAFLD and the diagnosis of cirrhosis have been accepted but not 
fully implemented, partly due to the lack of resources for markers of fibrosis and transient 
elastography. With respect to provision of services (Recommendations 2 and 3 of the 
previous report) a single Regional Liver Unit in Belfast, currently with four hepatologists 
(0.22 per 100,000 population) is planning to expand to five hepatologists in 2018.  Most of 
the nine hospitals outside Belfast have at least one gastroenterologist with an interest in liver 
health as a result of appointments over the past five years.  The adult liver transplant service 
for NI, which is based in Belfast and supported by Kings College Hospital, London, is 
delivering an appropriate number of transplants per head of population compared to rest of 
UK (20-24 per year) and has achieved the best one and five year survival figures amongst all 
UK transplant units. 
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An Alcohol Use Disorder care pathway was launched by the Public Health Authority in 2017 
and has been adopted by all Trusts across the region, which is helping with Recommendation 
5 of the Lancet Commission.  There are also plans to appoint more substance misuse liaison 
nurses across NI before end of 2017. A regional report on Alcohol Related Brain Damage is 
due to be published imminently and a specialist ARLD unit has been established in the South 
Eastern Health and Social Care (HSC) Trust. Funding for an Alcohol Assertive Outreach 
Liaison which had been successfully established in Belfast HSC Trust has unfortunately not 
been renewed and there has been no further expansion in numbers (currently 98) of alcohol 
specialist nurses across the five Trusts. 
Wales 
The Public Health (Wales) Bill, passed on the 17th May, commits the Welsh Government to 
produce an obesity prevention strategy. A series of round table events in the Senedd led to 
engagement with Assembly members over the importance of Hepatitis C as a public health 
concern. Cross party support was achieved for the Welsh Government to commit to the WHO 
elimination target date of 2030 and a strategy framework is now in development. Having 
treated all patients with Hepatitis C known to secondary care services, attention is now being 
focussed on improving testing rates, especially in hard to reach groups including a pilot 
project for blood born virus (BBV) testing in needle exchange pharmacy settings.  
In addition, the national liver strategy is investing in a burgeoning wellness services targeted 
at those who rarely contact health care services. The BBV module of the Wales Harm 
Reduction Database (used by community substance misuse services) has now been 
introduced across the country, covering consent, screening, testing, diagnosis and referral to 
specialist treatment services. An opt-out has been introduced for BBV testing in prisons, 
leading to testing and completion of HBV vaccination rates doubling since introduction.  
The ongoing commitment to enhancing alcohol care teams in Welsh Hospitals has led to an 
increase in the number of Alcohol Liaison Nurses from thirteen to twenty-one and four of six 
Welsh Health Boards now have an alcohol clinical lead. Following on from the pilot study of 
“reflex” AST testing when the ALT is abnormal, this has now been identified as a clinical 
priority area within the GP contract for Wales for 2017-2018. A GP Liver Disease Champion 
has been appointed in each Health Board for two years, supported by the National Strategy 
and with a specific remit to improve adherence to the BSG guideline on abnormal LFT and 
the development of a NAFLD pathway. A programme of work with IQILS has also been 
commissioned that will see all health boards go through this service improvement and 
accreditation process over the next three years. 
The national clinical leads for liver disease, diabetes, cardiac disease, stroke and cancer have 
identified obesity as a high priority area for collaborative working and the current utility of 
the National Exercise Referral Scheme (NERS) will also be evaluated as part of a wider 
approach to obesity management. Finally, funding has been set aside for a data officer 
dedicated to improve the clinical coding of liver disease which will cover GP coding methods 
and in the outpatient setting via the use of the Welsh Clinical Portal. 
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